ABDX Abingdon Health Plc
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company also engages in manufacturing of lateral flow devices; and provision of support in meeting compliance requirements in international IVD and medical device markets. Its diagnostic products include PCRD: Nucleic acid lateral flow, a rapid, portable nucleic acid detection; Abingdon simply test, a consumer self-test supplied to retailers, pharmacies, and healthcare providers; Pocket Diagnostic, a rapid lateral flow for agritech, including plant health test; and Appdx, a patented smartphone reader software which turns a phone camera into an accurate lateral flow reader with secure data capture. In addition, the company provides analytical services comprising laboratory, clinical trials and CRO, and medical device bioburden and biocompatibility; and AI, software and digital health, regulatory affairs, quality management systems, consultancy, PRRC and outsourced support, technical documentation, and audit readiness and risk management services. Further, it offers regulatory and other consultancy services to businesses in the diagnostics and medtech sectors. Abingdon Health Plc was incorporated in 2008 and is based in York, the United Kingdom.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Abingdon Health (LON: ABDX)
›
Abingdon Health (LON: ABDX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 131 employees.
The shares were at 8.500 GBp on 19 November 2026, up 36.0% over 52 weeks.
Its market capitalisation is 36.98M GBP.
Abingdon Health reports return on equity of -34.9%, an operating margin of -25.8% and revenue up 26.6% year over year.
It holds more cash than debt, a net cash position of 1.52M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 19.00 GBp is 123.5% above the current price.